Thus, although MAPK inhibitors would affect numerous intracellular signaling pathways and cellular functions, this result poses the question of whether available modulators of JNK and MAPK, already used in numerous clinical trials (49) might be useful alternatives for reversing the outcome of the prevailing MAFB/MAF ratio in lung macrophages in COVID-19. The gene discussed is MAFB; the disease is COVID-19.